DBC-664 in Adult Patients With Solid Tumors

DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.

Trial Details

NCT ID
NCT07705035
Phase
PHASE1
Sponsor
Duboce Biopharmaceuticals, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • DBC-664
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • East Brunswick, New Jersey, United States|40.42788,-74.41598
  • Lake Success, New York, United States|40.77066,-73.71763
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Must be ≥18 years of age at the time consent is signed.
  • Has a histologically or cytologically confirmed unresectable recurrent locally advanced or metastatic solid tumor
  • Has measurable disease per RECIST v1.1 (or mRECIST 1.1 for patients with pleural mesothelioma), as assessed by the local site Investigator/radiology.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →